Search

Author/Creator Ramchandren, R.

1. CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. (June 2017)

Authors:
Nayak, L.; Iwamoto, F.M.; Ferreri, A.J.; Santoro, A.; Singer, S.; Batlevi, C.; Batchelor, T.; Rubenstein, J.; Johnston, P.; Ramchandren, R.; Soussain, C.; Drappatz, J.; Becker, K.; Witzens‐Harig, M.; Illerhaus, G.; Herrera, A.; Masood, A.; Shipp, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
420
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. (June 2017)

Authors:
Herrera, A.F.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; Lacasce, A.S.; Ansell, S.M.; Moskowitz, C.H.; Fenton, K.; Ogden, C.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R.H.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
85
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL. (June 2017)

Authors:
Fanale, M.; Engert, A.; Younes, A.; Armand, P.; Ansell, S.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; De Boer, J.P.; Kuruvilla, J.; Savage, K.J.; Trneny, M.; Rodig, S.; Shipp, M.; Kato, K.; Sumbul, A.; Farsaci, B.; Santoro, A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP. (12th June 2019)

Authors:
Ansell, S.; Ramchandren, R.; Domingo‐Domènech, E.; Rueda, A.; Trněný, M.; Feldman, T.; Lee, H.; Provencio, M.; Sillaber, C.; Cohen, J.; Savage, K.; Willenbacher, W.; Sumbul, A.; Sacchi, M.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES (CITADEL‐101). (June 2017)

Authors:
Caimi, P.; Ramchandren, R.; Phillips, T.J.; Wertheim, M.S.; Gutierrez, M.E.; Edenfield, W.J.; Akard, L.P.; Call, J.A.; Persky, D.O.; DeMarini, D.J.; Zhou, L.; Yeleswaram, S.; Forero‐Torres, A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
268
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)

Authors:
Lee, H.; Flinn, I. W.; Melear, J.; Ramchandren, R.; Friedman, J.; Burke, J. M.; Linhares, Y.; Raval, M.; Chintapatla, R.; Feldman, T. A.; Yimer, H.; Islas-Ohlmayer, M.; Dean, A.; Rana, V.; Gandhi, M. D.; Renshaw, J.; Gillespie-Twardy, A. L.; Ho, L.; Puhlmann, M.; Guo, W.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
979
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. (23rd June 2022)

Authors:
Joffe, E.; Nowakowski, G.; Tun, H.; Rosenthal, A.; Lunning, M.; Ramchandren, R.; Li, C.-C.; Zhou, L.; Martinez, E.; von Roemeling, R.; Earhart, R.; McMahon, M.; Isufi, I.; Leslie, L.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1011
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML. (23rd June 2022)

Authors:
Daver, N.; Maris, M.; Ramchandren, R.; Bixby, D.; Doucette, K.; Mawad, R.; Egan, D.; Stevens, D.; Zonder, J.; Molloy, N.; Scheuber, A.; Bruns, I.; Mantzaris, I.; Konopleva, M.; Goldberg, A. D.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1700
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS. (12th June 2019)

Authors:
Diefenbach, C.; Kahl, B.; Banerjee, L.; McMillan, A.; Ramchandren, R.; Miall, F.; Briones, J.; Cordoba, R.; Gonzalez‐Barca, E.; Panizo, C.; Hirata, J.; Chang, N.; Musick, L.; Abrisqueta, P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
175
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. (12th June 2019)

Authors:
Wang, M.; Ramchandren, R.; Chen, R.; Karlin, L.; Chong, G.; Jurczak, W.; Wu, K.; Bishton, M.; Collins, G.; Eliadis, P.; Peyrade, F.; Freise, K.; Sukbuntherng, J.; Lee, Y.; Dobkowska, E.; Fedorov, V.; Neuenburg, J.; Tam, C.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
333
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗